Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

The Impact of Dry Eye Disease on Patients



ReachMD Healthcare Image

What challenges does DED present to patients, and what does early treatment do to improve their symptoms?

Please See

Indication and Important Safety Information

  • Sponsored by

  • Overview

    This episode features Leslie O’Dell, OD of Medical Optometry of America – Shrewsbury in Freedom, PA; Walter Whitley, OD of Virginia Eye Consultants in Norfolk, VA; and Eric Donnenfeld, MD of OCLI Vision, Garden Centre, NY. These physicians are consultants for Novartis and compensated for their time.

    What are patients looking to achieve from their dry eye treatment, and how can Xiidra help? Tune in to hear from eye care physicians.

    Sponsored by Novartis Pharmaceuticals Corporation

    4/23     275234


    Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).


    • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
    • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
    • To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
    • Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
    • Safety and efficacy in pediatric patients below the age of 17 years have not been established.

    Click here for Full Prescribing Information.

Schedule1 Jun 2023